Research Site
Florianópolis, Brazil
Location status: Recruiting
NCT Number: NCT07361276
This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).
Interested in participating?
Request Info18 year and older
All sexes
Observational
Florianópolis, Brazil
Location status: Recruiting
This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).
The retrospective cohort design allows for efficient use of existing clinical data to evaluate real-world practice against national guideline recommendations. The primary outcomes relate to treatment decisions and delays rather than interventional effects; therefore, an observational design is methodologically appropriate and ethically preferable.
The study will be conducted across 05 Brazilian municipalities participating in the epHealth Primary Care Solutions platform. These municipalities span multiple regions and reflect heterogeneity in socio-demographic context, healthcare infrastructure, and epidemiological profiles.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: through study completion, an average of 1 year
Proportion of patients with uncontrolled blood pressure (BP ≥ 140/90 mmHg) who did not receive treatment intensification within 3 months of a recorded elevated BP.
Time frame: through study completion, an average of 1 year
Proportions receiving monotherapy vs. combination therapy; distribution by pharmacologic class.
Time frame: through study completion, an average of 1 year
Likelihood of treatment escalation stratified by low/moderate vs. high/very high CV risk.
Contact information is provided by the study sponsor or research team.
AstraZeneca
Industry
Clinical Landscape of Epidemiology and Assessment of Results in Hypertension
Acronym: CLEAR-HTN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07310849
Arthritis, Arthritis, Gouty
New Taipei City, Wugu District, Taiwan
View Trial DetailsNCT07460882
Cardiovascular Diseases, Hypertension
Dhaka, Bangladesh
View Trial DetailsNCT07780500
Aldosterone Disorder, Cardiovascular Disease (CVD)
Oakland, California, United States
View Trial DetailsNCT06778239
Cardiovascular Diseases, Essential Hypertension
Bethesda, Maryland, United States
View Trial Details